Related Experiment Video
Updated: Sep 13, 2025

Operating Transverse Aortic Constriction with Absorbable Suture to Obtain Transient Myocardial Hypertrophy
Published on: September 9, 2020
[Surgical and percutaneous treatment of hypertrophic obstructive cardiomyopathy: state-of-the-art review]
Maria Sabrina Ferrante1, Calogera Pisano2, Giuseppe Maria Raffa3
1Centro Cuore, IRCCS - ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad alta specializzazione), Palermo.
Insights
Septal myectomy surgery is the gold standard for treating hypertrophic cardiomyopathy, effectively resolving left ventricular outflow tract obstruction. This surgical approach offers low mortality and morbidity rates in expert centers.
Area of Science:
- Cardiology
- Genetics
- Surgical Innovation
Background:
- Hypertrophic cardiomyopathy (HCM) is a complex, autosomal dominant genetic disorder.
- It stems from mutations in cardiac sarcomere protein genes.
- Current treatments vary, but surgical intervention remains a primary focus.
Purpose of the Study:
- To evaluate the efficacy of surgical septal myectomy in managing hypertrophic cardiomyopathy.
- To compare surgical outcomes with less invasive procedures.
- To highlight the benefits of surgical intervention in expert centers.
Main Methods:
- Review of existing treatment modalities for hypertrophic cardiomyopathy.
- Analysis of surgical septal myectomy (Morrow procedure).
- Comparison with alcohol septal ablation and mitral valve repair.
Main Results:
- Surgical septal myectomy demonstrates superiority in resolving left ventricular outflow tract obstruction.
- Surgery shows better outcomes regarding obstruction recurrence compared to other methods.
- The surgical approach is associated with low mortality and morbidity in specialized centers.
Conclusions:
- Septal myectomy is the gold standard treatment for obstructive hypertrophic cardiomyopathy.
- Surgery provides durable relief from left ventricular outflow tract obstruction.
- Expert surgical management of HCM ensures favorable patient outcomes.
Abstract:
Hypertrophic cardiomyopathy is a heterogeneous and complex disease. It is an autosomal dominant genetic disease caused by a missense mutation in one of at least 12 genes that code for cardiac sarcomere proteins. There are various approaches used today for the treatment of this pathology, but the "gold standard" remains the surgical treatment of septal myectomy according to Morrow, in which the hypertrophic septum is surgically excised. However, further less invasive approaches have been proposed, such as alcohol septal ablation and edge-to-edge repair of the systolic anterior motion of the mitral valve in patients who are not candidates for surgery, but the superiority of surgery in resolution of left ventricular outflow tract obstruction and its recurrence has been widely demonstrated. Moreover, the surgical approach is correlated with low mortality and morbidity rates in expert centers for the treatment of this pathology.
Related Concept Videos
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy VII: Pre and Post Operative Nursing Management
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Pericarditis III: Medical Management

